391 related articles for article (PubMed ID: 27796795)
21. [Treatment of refractory asthma with antibodies].
Lommatzsch M
Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
[TBL] [Abstract][Full Text] [Related]
22. Matching-adjusted indirect comparison of benralizumab
Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30309978
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
[TBL] [Abstract][Full Text] [Related]
24. The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review.
Patterson MF; Borish L; Kennedy JL
J Asthma Allergy; 2015; 8():125-34. PubMed ID: 26604804
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
Lim HF; Nair P
Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
27. Treating severe asthma: Targeting the IL-5 pathway.
Principe S; Porsbjerg C; Bolm Ditlev S; Kjaersgaard Klein D; Golebski K; Dyhre-Petersen N; van Dijk YE; van Bragt JJMH; Dankelman LLH; Dahlen SE; Brightling CE; Vijverberg SJH; Maitland-van der Zee AH
Clin Exp Allergy; 2021 Aug; 51(8):992-1005. PubMed ID: 33887082
[TBL] [Abstract][Full Text] [Related]
28. Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5.
Yanagibashi T; Satoh M; Nagai Y; Koike M; Takatsu K
Cytokine; 2017 Oct; 98():59-70. PubMed ID: 28863833
[TBL] [Abstract][Full Text] [Related]
29. Reslizumab: Maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.
Paton DM
Drugs Today (Barc); 2016 Jun; 52(6):323-9. PubMed ID: 27458609
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
Smith DA; Minthorn EA; Beerahee M
Clin Pharmacokinet; 2011 Apr; 50(4):215-27. PubMed ID: 21348536
[TBL] [Abstract][Full Text] [Related]
31. Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study.
Vantaggiato L; Perruzza M; Refini RM; Bergantini L; d'Alessandro M; Cameli P; Perruzza D; Bini L; Bargagli E; Landi C
Lung; 2020 Oct; 198(5):761-765. PubMed ID: 32691140
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
33. Reslizumab in the treatment of severe eosinophilic asthma: an update.
Walsh GM
Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
[TBL] [Abstract][Full Text] [Related]
34. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.
Pelaia C; Calabrese C; Vatrella A; Busceti MT; Garofalo E; Lombardo N; Terracciano R; Pelaia G
Biomed Res Int; 2018; 2018():4839230. PubMed ID: 29862274
[TBL] [Abstract][Full Text] [Related]
35. Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab.
Landi C; Cameli P; Vantaggiato L; Bergantini L; d'Alessandro M; Perruzza M; Carleo A; Shaba E; Di Giuseppe F; Angelucci S; Bargagli E; Bini L
Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140563. PubMed ID: 33176218
[TBL] [Abstract][Full Text] [Related]
36. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
[TBL] [Abstract][Full Text] [Related]
37. [PERSONALIZED TREATMENT OF ASTHMA: THE ISSUE OF ANTI-INTERLEUKIN-5 ANTIBODIES].
Louis R; Demarche S; Van Hees T; Schleich F
Rev Med Liege; 2015; 70(5-6):306-9. PubMed ID: 26285457
[TBL] [Abstract][Full Text] [Related]
38. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
[TBL] [Abstract][Full Text] [Related]
39. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):469-476. PubMed ID: 31136272
[TBL] [Abstract][Full Text] [Related]
40. Mepolizumab treatment for asthma.
Robinson DS
Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
